移植用HLAタイピング市場：製品・サービス、技術、移植タイプ、用途、エンドユーザー別-2025-2030年世界予測

移植用HLAタイピング市場は、2023年に9億9,831万米ドルと評価され、2024年には10億8,639万米ドルに達すると予測され、CAGR 9.09%で成長し、2030年には18億3,658万米ドルに達すると予測されています。

移植用HLAタイピングは、臓器や組織のドナーのヒト白血球抗原（HLA）とレシピエントのヒト白血球抗原（HLA）をマッチングさせ、適合性を確保し、拒絶反応のリスクを軽減する、医学における重要な手順です。このプロセスは、腎臓、肝臓、心臓、骨髄移植などの臓器移植において不可欠であり、正確な適合が移植の成功率と寿命に大きく影響します。HLAタイピングの市場は、主に臓器不全の発生率の上昇と世界の臓器移植需要の増加によって牽引されています。さらに、特に分子診断における技術の進歩がHLAタイピングの精度と効率を向上させ、病院と研究所の両方におけるHLAタイピングの応用を後押ししています。主な成長要因としては、臓器提供に対する意識の高まり、移植活動を支援する政府のイニシアチブの増加、臓器不全につながる慢性疾患の有病率の増加などが挙げられます。しかし、HLAタイピングのコストが高いこと、臓器の入手可能性が限られていること、臓器移植をめぐる倫理的懸念などの課題が市場成長の抑制要因となっています。とはいえ、特に次世代シーケンシングの進歩や個別化医療の広がりなど、この分野にはビジネスチャンスがあふれています。自動HLAタイピング技術やハイスループットHLAタイピング技術などの分野で技術革新を進める企業は、競争優位に立てる可能性があります。ヘルスケア・インフラが急速に改善しつつある新興市場での事業拡大も、市場参入企業にとって有利な機会となります。このような潜在的利益にもかかわらず、厳しい規制の枠組みや照合プロセスの複雑さは、依然として大きなハードルとなっています。今後の研究では、費用対効果の高い技術の最適化と、HLAマッチングのスピードアップに焦点を当て、アクセシビリティと効率性を高めることが期待されます。同市場は、技術革新と技術的進歩に対する継続的な需要が特徴であり、研究開発に投資し、デジタルヘルスケアソリューションを採用する主要企業が市場シェアを獲得する可能性が高いことを示唆しています。

市場力学：急速に進化する移植用HLAタイピング市場の主要市場インサイトを公開

移植用HLAタイピング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 骨髄、臓器、血液移植プロセスの発生率の上昇
  • 移植片拒絶反応の減少を目的とした個別化医療におけるHLAタイピングの採用
• 市場抑制要因
  • 償還不足と不十分な保険政策
• 市場機会
  • 移植診断およびHLAタイピング法の分野における技術の進歩
  • HLAタイピングを補完する免疫抑制療法の選好
• 市場の課題
  • HLAタイピングの不正確さに関する懸念

ポーターの5つの力：移植用HLAタイピング市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：移植用HLAタイピング市場における外部からの影響の把握

外部マクロ環境要因は、移植用HLAタイピング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析移植用HLAタイピング市場における競合情勢の把握

移植用HLAタイピング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス移植用HLAタイピング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、移植用HLAタイピング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 骨髄、臓器、血液の移植手術の発生率の上昇
    • 移植片拒絶反応を減らすための個別化医療におけるHLAタイピングの採用
  • 抑制要因
    • 補償の不足と不十分な保険
  • 機会
    • 移植診断とHLAタイピング法の分野における技術的進歩
    • HLAタイピングを補完する免疫抑制療法の優先
  • 課題
    • HLAタイピングの不正確さに関する懸念
• 市場セグメンテーション分析
  • 技術：高い特異性と再現性を備えた分子アッセイ技術の採用
  • 製品とサービス：データの解釈と研究室のワークフロー管理を容易にするソフトウェアとサービスの優先
  • 移植の種類：白血病、リンパ腫、骨髄腫、免疫系疾患に対する幹細胞移植療法の利用が増加
  • 応用：臓器移植の診断アプリケーションにおけるHLAタイピングの使用
  • エンドユーザー：独立したリファレンスラボに高い浸透率で、高スループット機能と拡張性を実現
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 移植用HLAタイピング市場：製品・サービス別

• 機器
• 試薬・消耗品
• ソフトウェアとサービス

第7章 移植用HLAタイピング市場：技術別

• 分子アッセイ技術
  • PCRベースの分子アッセイ
    • リアルタイムPCR
    • 配列特異的オリゴヌクレオチドPCR
    • 配列特異的プライマーPCR
  • シーケンシングに基づく分子アッセイ
    • 次世代シーケンシング
    • サンガーシーケンス
• 非分子アッセイ技術

第8章 移植用HLAタイピング市場移植タイプ別

• 臓器移植
• 幹細胞移植
• 組織移植

第9章 移植用HLAタイピング市場：用途別

• 診断アプリケーション
  • 抗体スクリーニング
  • キメリズムモニタリング
• 調査アプリケーション

第10章 移植用HLAタイピング市場：エンドユーザー別

• 臨床検査室・調査機関
• 病院と移植センター
• 独立リファレンスラボ

第11章 南北アメリカの移植用HLAタイピング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の移植用HLAタイピング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの移植用HLAタイピング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • GenDxがNGS-Turboを発売：Oxford Nanopore Technologiesのシーケンシングデバイスで高解像度 HLAタイピングに革命をもたらす
  • Omixonは、オックスフォードナノポアのMinIONプラットフォームと互換性のあるシングルプレックスヒト白血球抗原増幅キット NanoTYPE MONOおよびMONOall RUOを発売しました。
  • JURA Bio、がんにおけるT細胞受容体NK療法の発展に向け、リプレイ製品会社Syenaとの提携を発表
  • オッシウム・ヘルスとビー・ザ・マッチが骨髄移植のアクセス性と治療効率を高めるための提携を発表
  • BriaCellががんプラットフォーム開発のためのNCI助成金を受領
  • TempusがTScan Therapeuticsとのコンパニオン診断コラボレーションを発表
  • メトロポリス・ヘルスケアが臓器移植用の次世代HLA検査を発表
  • CD Genomics Longseq部門がヒト白血球抗原（HLA）タイピングサービスを発表
  • ガルーダ・セラピューティクス、既製の血液幹細胞技術プラットフォームの発展に向けて6,200万米ドルのシリーズB資金調達を確保
  • FDAは転移性または切除不能なブドウ膜黒色腫に対するT細胞受容体療法の補助診断として使用するためにHLAタイピング検査にDe Novo分類を付与しました。
  • ユーロバイオサイエンティフィックがジェンDxを1億3,230万米ドルで買収
  • Be The Match BioTherapiesとAtara Biotherapeuticsが複数年にわたるパートナーシップ契約を延長

企業一覧

• Takara Bio Inc.
• Chugai Pharmaceutical Co., Ltd.
• CapitalBio Technology Co., Ltd.
• Pure MHC, LLC
• Laboratory Corporation of America Holdings
• TCR2 Therapeutics by Adaptimmune Therapeutics PLC
• Bio-Techne Corporation
• NeoGenomics Laboratories, Inc.
• Oxford Nanopore Technologies PLC
• Pure Protein, LLC
• OraSure Technologies, Inc.
• CareDx, Inc.
• DiaSorin S.p.A.
• BAG Diagnostics GmbH
• GenDx by Eurobio Scientific Group
• TBG Diagnostics Ltd.
• QIAGEN N.V.
• HEALIOS K.K.
• Thermo Fisher Scientific, Inc.
• Merck KGaA
• Illumina, Inc.
• BGI Genomics Co.,Ltd.
• Becton, Dickinson, and Company
• Hologic, Inc.
• Bio-Rad Laboratories, Inc.
• Lonza Group Ltd.
• STEMCELL Technologies Inc.
• F. Hoffman-La Roche AG
• CeGaT GmbH
• Fujirebio, Inc. by H.U. Group Holdings, Inc.
• Eurofins Scientific SE
• Invectys Inc.
• Creative Biolabs, Inc.
• ImmunOs Therapeutics AG
• Immucor, Inc. by Werfen, S.A.
• Immatics N.V.
• T-Cure Bioscience Inc.
• Agilent Technologies, Inc.
• Garuda Therapeutics

LIST OF FIGURES

• FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
• FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
• TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 67. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 68. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 69. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 70. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 71. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 74. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 81. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 82. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 83. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 92. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 99. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 101. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 102. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 107. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 108. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 109. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 111. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 112. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 114. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 116. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 117. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 118. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 119. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 121. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 123. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 124. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 125. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 126. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 127. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 130. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 132. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 133. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 134. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 135. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 136. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 139. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 141. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 142. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 143. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 144. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 145. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 147. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 148. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 150. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 152. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 153. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 154. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 155. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 157. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 159. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 160. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 161. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 162. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 163. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 166. PHILIPPINES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 168. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 169. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 170. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 171. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 172. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 175. SINGAPORE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 177. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 178. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 179. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 180. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 181. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 183. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 184. SOUTH KOREA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 185. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 186. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 187. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 188. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 189. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 190. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 193. TAIWAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 195. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 197. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 198. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 199. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 200. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 201. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 202. THAILAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 204. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 205. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 206. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 207. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 208. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 209. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 211. VIETNAM HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 222. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 223. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 224. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 225. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 226. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 227. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 228. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 230. DENMARK HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 232. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 234. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 235. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 236. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 237. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 238. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 239. EGYPT HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 240. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 241. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 242. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 243. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 244. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 245. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 246. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 248. FINLAND HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 249. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 250. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 251. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 252. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 253. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 254. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 255. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 256. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 257. FRANCE HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 259. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 260. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 261. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 262. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 263. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 264. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 266. GERMANY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 267. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 268. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 269. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 270. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 271. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 272. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 273. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 274. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 275. ISRAEL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 277. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 278. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 279. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 280. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 281. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 282. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 284. ITALY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 285. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 286. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 287. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 288. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 289. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 290. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 291. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 292. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 293. NETHERLANDS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 294. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 295. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 296. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 297. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 298. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2030 (USD MILLION)
• TABLE 299. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2030 (USD MILLION)
• TABLE 300. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 301. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2030 (USD MILLION)
• TABLE 302. NIGERIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 303. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 304. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 305. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2030 (USD MILLION)
• TABLE 306. NORWAY HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR

The HLA Typing for Transplant Market was valued at USD 998.31 million in 2023, expected to reach USD 1,086.39 million in 2024, and is projected to grow at a CAGR of 9.09%, to USD 1,836.58 million by 2030.

HLA typing for transplant is a crucial procedure in medical science that involves matching the human leukocyte antigens (HLA) of organ and tissue donors with those of recipients to ensure compatibility and reduce the risk of rejection. This process is vital in organ transplantation, including kidney, liver, heart, and bone marrow transplants, where precise matching can significantly influence the success rate and longevity of the transplant. The market for HLA typing is primarily driven by the rising incidence of organ failure and the increasing demand for organ transplants globally. Additionally, advancements in technology, particularly in molecular diagnostics, have enhanced the precision and efficiency of HLA typing, propelling its application in both hospitals and research laboratories. Key growth influencers include the rising awareness about organ donation, increasing government initiatives supporting transplantation activities, and the growing prevalence of chronic diseases leading to organ failure. However, challenges such as the high cost of HLA typing procedures, limited availability of organs, and ethical concerns surrounding organ transplantation act as restraints to market growth. Nevertheless, opportunities abound in the sector, particularly with the advancements in next-generation sequencing and the scope for personalized medicine. Companies poised to innovate in fields like automated and high-throughput HLA typing technologies may gain a competitive edge. Expansions in emerging markets, where healthcare infrastructure is rapidly improving, also present lucrative opportunities for market players. Despite these potential gains, stringent regulatory frameworks and the complexity of matching processes remain significant hurdles. Future research could focus on optimizing cost-effective techniques and improving the speed of HLA matching to enhance accessibility and efficiency. The market is characterized by a continuous demand for innovation and technological advancements, suggesting that companies investing in R&D and adopting digital healthcare solutions will likely lead in capturing market share.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HLA Typing for Transplant Market

The HLA Typing for Transplant Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of bone marrow, organ, and blood transplant processes
  • Adoption of HLA typing in personalized medicine for reduced graft rejections
• Market Restraints
  • Lack of reimbursement and inadequate insurance policies
• Market Opportunities
  • Technological advancements in the field of transplant diagnostics and HLA-typing methods
  • Preference for immunosuppressive therapies to complement HLA typing
• Market Challenges
  • Concerns regarding the inaccuracy of HLA typing

Porter's Five Forces: A Strategic Tool for Navigating the HLA Typing for Transplant Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HLA Typing for Transplant Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HLA Typing for Transplant Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HLA Typing for Transplant Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HLA Typing for Transplant Market

A detailed market share analysis in the HLA Typing for Transplant Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HLA Typing for Transplant Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HLA Typing for Transplant Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Takara Bio Inc., Chugai Pharmaceutical Co., Ltd., CapitalBio Technology Co., Ltd., Pure MHC, LLC, Laboratory Corporation of America Holdings, TCR2 Therapeutics by Adaptimmune Therapeutics PLC, Bio-Techne Corporation, NeoGenomics Laboratories, Inc., Oxford Nanopore Technologies PLC, Pure Protein, LLC, OraSure Technologies, Inc., CareDx, Inc., DiaSorin S.p.A., BAG Diagnostics GmbH, GenDx by Eurobio Scientific Group, TBG Diagnostics Ltd., QIAGEN N.V., HEALIOS K.K., Thermo Fisher Scientific, Inc., Merck KGaA, Illumina, Inc., BGI Genomics Co.,Ltd., Becton, Dickinson, and Company, Hologic, Inc., Bio-Rad Laboratories, Inc., Lonza Group Ltd., STEMCELL Technologies Inc., F. Hoffman-La Roche AG, CeGaT GmbH, Fujirebio, Inc. by H.U. Group Holdings, Inc., Eurofins Scientific SE, Invectys Inc., Creative Biolabs, Inc., ImmunOs Therapeutics AG, Immucor, Inc. by Werfen, S.A., Immatics N.V., T-Cure Bioscience Inc., Agilent Technologies, Inc., and Garuda Therapeutics.

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product & Service, market is studied across Instruments, Reagents & Consumables, and Software & Services.
• Based on Technology, market is studied across Molecular Assay Technologies and Non-Molecular Assay Technologies. The Molecular Assay Technologies is further studied across PCR-Based Molecular Assays and Sequencing-Based Molecular Assays. The PCR-Based Molecular Assays is further studied across Real-Time PCR, Sequence-Specific Oligonucleotide-PCR, and Sequence-Specific Primer-PCR. The Sequencing-Based Molecular Assays is further studied across Next-Generation Sequencing and Sanger Sequencing.
• Based on Transplant Type, market is studied across Organ Transplantation, Stem Cell Transplantation, and Tissue Transplantation.
• Based on Application, market is studied across Diagnostic Applications and Research Applications. The Diagnostic Applications is further studied across Antibody Screening and Chimerism Monitoring.
• Based on End-User, market is studied across Clinical Laboratories & Research Institution, Hospitals & Transplant Centers, and Independent Reference Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
    • 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of reimbursement and inadequate insurance policies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
    • 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
  • 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
  • 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
  • 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
  • 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. HLA Typing for Transplant Market, by Product & Service

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents & Consumables
• 6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

• 7.1. Introduction
• 7.2. Molecular Assay Technologies
  • 7.2.1. PCR-Based Molecular Assays
    • 7.2.1.1. Real-Time PCR
    • 7.2.1.2. Sequence-Specific Oligonucleotide-PCR
    • 7.2.1.3. Sequence-Specific Primer-PCR
  • 7.2.2. Sequencing-Based Molecular Assays
    • 7.2.2.1. Next-Generation Sequencing
    • 7.2.2.2. Sanger Sequencing
• 7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

• 8.1. Introduction
• 8.2. Organ Transplantation
• 8.3. Stem Cell Transplantation
• 8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

• 9.1. Introduction
• 9.2. Diagnostic Applications
  • 9.2.1. Antibody Screening
  • 9.2.2. Chimerism Monitoring
• 9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

• 10.1. Introduction
• 10.2. Clinical Laboratories & Research Institution
• 10.3. Hospitals & Transplant Centers
• 10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
  • 14.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
  • 14.3.3. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
  • 14.3.4. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
  • 14.3.5. BriaCell receives NCI grant for cancer platform development
  • 14.3.6. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
  • 14.3.7. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
  • 14.3.8. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
  • 14.3.9. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
  • 14.3.10. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
  • 14.3.11. Eurobio Scientific acquires GenDx for USD 132.3 million
  • 14.3.12. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension

Companies Mentioned

• 1. Takara Bio Inc.
• 2. Chugai Pharmaceutical Co., Ltd.
• 3. CapitalBio Technology Co., Ltd.
• 4. Pure MHC, LLC
• 5. Laboratory Corporation of America Holdings
• 6. TCR2 Therapeutics by Adaptimmune Therapeutics PLC
• 7. Bio-Techne Corporation
• 8. NeoGenomics Laboratories, Inc.
• 9. Oxford Nanopore Technologies PLC
• 10. Pure Protein, LLC
• 11. OraSure Technologies, Inc.
• 12. CareDx, Inc.
• 13. DiaSorin S.p.A.
• 14. BAG Diagnostics GmbH
• 15. GenDx by Eurobio Scientific Group
• 16. TBG Diagnostics Ltd.
• 17. QIAGEN N.V.
• 18. HEALIOS K.K.
• 19. Thermo Fisher Scientific, Inc.
• 20. Merck KGaA
• 21. Illumina, Inc.
• 22. BGI Genomics Co.,Ltd.
• 23. Becton, Dickinson, and Company
• 24. Hologic, Inc.
• 25. Bio-Rad Laboratories, Inc.
• 26. Lonza Group Ltd.
• 27. STEMCELL Technologies Inc.
• 28. F. Hoffman-La Roche AG
• 29. CeGaT GmbH
• 30. Fujirebio, Inc. by H.U. Group Holdings, Inc.
• 31. Eurofins Scientific SE
• 32. Invectys Inc.
• 33. Creative Biolabs, Inc.
• 34. ImmunOs Therapeutics AG
• 35. Immucor, Inc. by Werfen, S.A.
• 36. Immatics N.V.
• 37. T-Cure Bioscience Inc.
• 38. Agilent Technologies, Inc.
• 39. Garuda Therapeutics